SAbR-induced Innate Immunity

2016-12-08 17:38:27 | BioPortfolio


The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR. Tumor core biopsies will be processed and analyzed as described above. Medical records electronic medical records will be used to collect demographic and medical information and imaging studies.


Within 2 weeks of planned SAbR, patients will have a core biopsy of the lesion to receive SAbR. Laboratory values will be obtained prior to biopsy. Once the laboratory values are found to be within the safe margin for biopsy, multiple (approximately 5) core biopsies will be obtained with an 18-guage or 19-gauge needle under CT or US guidance. Tissue will be snap frozen with liquid nitrogen and immediately transferred to the laboratory of Dr. Zhijian "James" Chen, PhD, Professor, Department of Molecular Biology NA6.120, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390-9148, 214-648-1145 (phone) and attention: Beethoven Ramirez and Dr. Tuo Li.

SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called "radiated" lesions. Prior irradiated lesions will be excluded. SABR will be administered within 2 weeks of the study initial core biopsy. The SAbR dose and fractionation scheme is generated to deliver a potent dose to ablate the targeted lesions and at the same time maximize an immune response. Since multiple studies have shown an influx of lymphocytes and monocytes after tumor irradiation (Lugade, 2005; Rubner, 2012; Takeshima, 2010; Lee, 2009) and since these cells play a critical role in antigen presentation and initiation of an adaptive immune response, multiple fraction irradiation which would kill these infiltrating immunocytes, is discouraged. Therefore a single fraction or a three fraction treatment regimen is recommended, and a single fraction treatment is preferred over three fractions. Due to normal organ toxicity and limits of dose constraints, sometimes a three fraction treatment must be undertaken and in those cases it is recommended that the treatment course is completed within 7- 10 days--preferably 5 business days. Radiation dose-immune response studies have shown a linear increase in immune response with increased dose per fraction of radiation without demonstration of a plateau (Lugade, 2005; Lee, 2009; Reits, 2006; Schaue, 2012). Two studies comparing 15Gy x 1 vs 5Gy x3, and 20Gy x1 vs 5Gy x4 have shown a superior immune response generated by the single fraction radiation (Lugade, 2005; Lee, 2009). Clinical experience with oligometastatic patients treated at 1-5 sites of disease has also showed an increase in progression-free survival with the increasing radiation dose per fraction (Salama, 2012). A dose of less than 7.5 Gy per fraction has demonstrated lower induction of systemic IFN-γ producing cells (Schaue, 2012), and a previous phase II study of mRCC patients treated with HD IL-2 and singe fraction of 8Gy irradiation to a single lesion did not show an overall improvement in response rate (Redman, 1998). Therefore 8Gy per fraction is the lowest permitted dose for this study and can be used only when administering the three fraction regimen as described in the prescription dose table below. Investigators will have discretion in choosing from either of the biologically equivalent dose levels using one or three fractions, although a single fraction is preferred over three fraction treatments. Treating physician will have further discretion in selecting the number and location of sites to treat if multiple sites of disease are present. Maximum number of lesions treated is deemed as feasible per the treating radiation oncologist. However, for the purposes of this protocol, only a single site will be studied and must be safely amenable to repeat core biopsy. Thus, the single site for the study will be either in subcutaneous tissues, nodes, isolated masses or liver. The gross target/tumor volume--GTV should be at least 2 cm3 in size, corresponding to roughly a 1.5 cm diameter tumor. This is to ensure that adequate tumor volume for therapy and for biopsy and therefore adequate tumor cells roughly 108 -109 cells/cm3 (Del Monte, 2009) are killed for antigen presentation. Treating physicians should choose their dose based on established planning guidelines at their center including their ability to respect normal tissue tolerance.

Within 24 + 6 hours of the first SAbR, a second core biopsy of the "target" irradiated lesion will be performed identically to the first biopsy.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Urothelial Carcinoma


SAbR Treatment of Lesions


Not yet recruiting


University of Texas Southwestern Medical Center

Results (where available)

View Results


Published on BioPortfolio: 2016-12-08T17:38:27-0500

Clinical Trials [1796 Associated Clinical Trials listed on BioPortfolio]

Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung. ...

A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma

The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harbo...

Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

Primary Objective: To study if lycopene can improve the biomarker status of urothelial cells in patients with uremia-associated urothelial carcinoma. Secondary Objective: To evaluate the ...

Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection

The purpose of this study is to learn if ipilimumab can be given safely at two different doses given to patients with urothelial cancer who are going to have surgery as part of their treat...

Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy

In this single-arm trial we will investigate the safety of short-term preoperative therapy with ipilimumab and nivolumab in patients with high-risk resectable urothelial cancer. We will de...

PubMed Articles [20937 Associated PubMed Articles listed on BioPortfolio]

Immunotherapy Advances in Urothelial Carcinoma.

Checkpoint inhibitors have monumentally transformed the treatment of metastatic urothelial carcinoma. While the efficacy and safety of the different agents are similar in platinum-refractory metastati...

Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma.

Current literature supports the efficacy of anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors for the treatment of urothelial carcinomas. While the prognostic value of PD-1 and PD-L1 levels has be...

Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.

The use of systemic immunotherapy targets is emerging as an important treatment option for metastatic urothelial carcinoma, particularly for patients who cannot tolerate or who fail cisplatin-based ch...

Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.

The optimal treatment of urothelial bladder cancer (UBC) with micropapillary (MP) variant histology is not clear.

Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines.

While radical nephroureterectomy (RNU) is the gold standard treatment for upper tract urothelial carcinoma (UTUC), select patients may benefit from endoscopic treatment (ET). European Association of U...

Medical and Biotech [MESH] Definitions

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

White or pink lesions on the arms, hands, face, or scalp that arise from sun-induced DNA DAMAGE to KERATINOCYTES in exposed areas. They are considered precursor lesions to superficial SQUAMOUS CELL CARCINOMA.

6,17-Dimethylpregna-4,6-diene-3,20-dione. A synthetic progestational hormone with actions similar to those of progesterone. It is used in the treatment of menstrual irregularities and has also been employed in the treatment of prostatic hypertrophy and endometrial carcinoma.

A condition in which abnormal cells have not spread outside the duct, lobule, or nipple to other tissues of the breast. There are 3 types of breast carcinoma in situ: DUCTAL CARCINOMA IN SITU; LOBULAR CARCINOMA IN SITU; and PAGET DISEASE OF THE NIPPLE

A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)

More From BioPortfolio on "SAbR-induced Innate Immunity"

Quick Search


Relevant Topics

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Searches Linking to this Trial